Research ArticleTUMOR IMMUNOLOGY

Myeloid cell–synthesized coagulation factor X dampens antitumor immunity

See allHide authors and affiliations

Science Immunology  20 Sep 2019:
Vol. 4, Issue 39, eaaw8405
DOI: 10.1126/sciimmunol.aaw8405

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Targeting factor Xa to promote antitumor immunity

Secreted molecules including cytokines regulate immune cell functions in the tumor microenvironment (TME). Here, Graf et al. report that myeloid cells in the TME produce coagulation factor X that dampens antitumor immune responses and that targeted deletion of factor X in myeloid cells impaired tumor growth in multiple mouse tumor models. Further, they show that rivaroxaban, a factor Xa inhibitor that is used in the clinic as an anticoagulant is effective at promoting systemic antitumor immunity in mouse models. The preclinical findings by Graf et al. also make the case for administering rivaroxaban in combination with therapies targeting the programmed cell death protein 1.

View Full Text